NASDAQ:DARE Dare Bioscience Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dare Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.04 -0.02 (-1.89 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$1.03Now: $1.04▼$1.1050-Day Range$1.02MA: $1.11▼$1.2052-Week Range$0.69Now: $1.04▼$2.22Volume737,904 shsAverage Volume439,175 shsMarket Capitalization$32.81 millionP/E RatioN/ADividend YieldN/ABeta1.9 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder. The company has license and collaboration agreement with Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC to develop and commercialize indications for women related to female sexual dysfunction and/or female reproductive health. The company was incorporated in 2005 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingDare Bioscience has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.50, Dare Bioscience has a forecasted upside of 332.7% from its current price of $1.04.Amount of Analyst CoverageDare Bioscience has only been the subject of 3 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesDare Bioscience has received 323 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDare Bioscience has received 234 “underperform” votes. (Add your “underperform” vote.)Community SentimentDare Bioscience has received 57.99% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dare Bioscience and other stocks. Vote “Outperform” if you believe DARE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DARE will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDare Bioscience does not currently pay a dividend.Dividend GrowthDare Bioscience does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dare Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Dare Bioscience is held by insiders.Percentage Held by InstitutionsOnly 5.15% of the stock of Dare Bioscience is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dare Bioscience are expected to grow in the coming year, from ($0.67) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dare Bioscience is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dare Bioscience is -1.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDare Bioscience has a P/B Ratio of 52.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.39 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DARE Previous Symbol CUSIPN/A CIK1401914 Webwww.darebioscience.com Phone858-926-7655Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book52.00Profitability EPS (Most Recent Fiscal Year)($0.97) Net Income$-14,260,000.00 Net MarginsN/A Return on Equity-1,290.51% Return on Assets-247.57%Miscellaneous Employees5 Outstanding Shares31,550,000Market Cap$32.81 million Next Earnings Date11/12/2020 (Estimated) OptionableNot Optionable $1.04 -0.02 (-1.89 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DARE News and Ratings via Email Sign-up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Dare Bioscience (NASDAQ:DARE) Frequently Asked Questions How has Dare Bioscience's stock been impacted by COVID-19 (Coronavirus)? Dare Bioscience's stock was trading at $1.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DARE shares have increased by 3.0% and is now trading at $1.04. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Dare Bioscience? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dare Bioscience. When is Dare Bioscience's next earnings date? Dare Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Dare Bioscience. How were Dare Bioscience's earnings last quarter? Dare Bioscience Inc (NASDAQ:DARE) issued its quarterly earnings data on Wednesday, August, 12th. The biotechnology company reported ($0.27) EPS for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.13. View Dare Bioscience's earnings history. What price target have analysts set for DARE? 5 equities research analysts have issued 1 year price objectives for Dare Bioscience's shares. Their forecasts range from $3.00 to $7.50. On average, they expect Dare Bioscience's stock price to reach $4.50 in the next year. This suggests a possible upside of 332.7% from the stock's current price. View analysts' price targets for Dare Bioscience. Are investors shorting Dare Bioscience? Dare Bioscience saw a decline in short interest in August. As of August 31st, there was short interest totaling 161,900 shares, a decline of 20.8% from the August 15th total of 204,500 shares. Based on an average daily volume of 929,000 shares, the days-to-cover ratio is currently 0.2 days. View Dare Bioscience's Short Interest. Who are some of Dare Bioscience's key competitors? Some companies that are related to Dare Bioscience include Evolus (EOLS), Tyme Technologies (TYME), Evoke Pharma (EVOK), Inflarx (IFRX), Corvus Pharmaceuticals (CRVS), Zosano Pharma (ZSAN), Lumos Pharma (LUMO), Tonix Pharmaceuticals (TNXP), Strongbridge Biopharma (SBBP), Sierra Oncology (SRRA), Mallinckrodt (MNK), Leap Therapeutics (LPTX), OASMIA PHARMACE/ADR (OASM), Vaccinex (VCNX) and Unum Therapeutics (UMRX). View all competitors. What other stocks do shareholders of Dare Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dare Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), Novavax (NVAX), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Heat Biologics (HTBX), Matinas BioPharma (MTNB) and SCYNEXIS (SCYX). Who are Dare Bioscience's key executives? Dare Bioscience's management team includes the following people: Ms. Sabrina Martucci Johnson, Pres, CEO, Sec. & Director (Age 52)Ms. Lisa Walters-Hoffert, Chief Financial Officer (Age 60)Mr. Mark Walters, VP of Operations (Age 64)Ms. MarDee J. Haring-Layton, VP of Accounting & Fin. (Age 43)Dr. David Friend, Chief Scientific Officer What is Dare Bioscience's stock symbol? Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE." Who are Dare Bioscience's major shareholders? Dare Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include Founders Financial Securities LLC (0.36%), Virtu Financial LLC (0.15%) and HighTower Advisors LLC (0.10%). View institutional ownership trends for Dare Bioscience. Which major investors are buying Dare Bioscience stock? DARE stock was acquired by a variety of institutional investors in the last quarter, including Founders Financial Securities LLC, Virtu Financial LLC, and HighTower Advisors LLC. View insider buying and selling activity for Dare Bioscience. How do I buy shares of Dare Bioscience? Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Dare Bioscience's stock price today? One share of DARE stock can currently be purchased for approximately $1.04. How big of a company is Dare Bioscience? Dare Bioscience has a market capitalization of $32.81 million. The biotechnology company earns $-14,260,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe. What is Dare Bioscience's official website? The official website for Dare Bioscience is www.darebioscience.com. How can I contact Dare Bioscience? Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
